Cereno Scientific: First patient, fresh momentum - Edison
Cereno Scientific has reached an inflection point in its clinical development, with the first patient randomised and dosed in the Phase IIb EPIMODE study of CS1 in pulmonary arterial hypertension (PAH).
ANNONS
This marks an encouraging transition into active treatment, following a slower-than-anticipated start to patient randomisation. Importantly, management has maintained its target of completing recruitment in 2027, with top-line results expected in Q428, suggesting limited impact on the broader development timeline.
EPIMODE represents the critical clinical validation step for CS1, with its extended 52-week treatment duration and two-stage design offering an opportunity to demonstrate sustained efficacy and potential disease modification, a key differentiator in PAH.
With clinical activities gathering momentum and the proposed financing package offering a potential funding pathway, we believe these developments should help rebuild investor confidence and support a more constructive outlook for Cereno.